These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 19920716)

  • 41. Transdermal opioids for cancer pain control in patients with renal impairment.
    Melilli G; Samolsky Dekel BG; Frenquelli C; Mellone R; Pannuti F
    J Opioid Manag; 2014; 10(2):85-93. PubMed ID: 24715663
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allergic contact dermatitis from transdermal buprenorphine.
    Vander Hulst K; Parera Amer E; Jacobs C; Dewulf V; Baeck M; Pujol Vallverdú RM; Giménez-Arnau A; Tennstedt D; Goossens A
    Contact Dermatitis; 2008 Dec; 59(6):366-9. PubMed ID: 19076888
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age.
    Likar R; Vadlau EM; Breschan C; Kager I; Korak-Leiter M; Ziervogel G
    Clin J Pain; 2008; 24(6):536-43. PubMed ID: 18574363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland.
    Przeklasa-Muszynska A; Dobrogowski J
    Curr Med Res Opin; 2011 Jun; 27(6):1109-17. PubMed ID: 21456888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.
    Sittl R; Griessinger N; Likar R
    Clin Ther; 2003 Jan; 25(1):150-68. PubMed ID: 12637117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of cancer-related pain with transdermal fentanyl.
    Leelanuntakit S
    J Med Assoc Thai; 1996 Jun; 79(6):341-6. PubMed ID: 8855606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transdermal fentanyl in the management of children with chronic severe pain: results from an international study.
    Finkel JC; Finley A; Greco C; Weisman SJ; Zeltzer L
    Cancer; 2005 Dec; 104(12):2847-57. PubMed ID: 16284992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of strong opioids in advanced cancer pain: a randomized trial.
    Marinangeli F; Ciccozzi A; Leonardis M; Aloisio L; Mazzei A; Paladini A; Porzio G; Marchetti P; Varrassi G
    J Pain Symptom Manage; 2004 May; 27(5):409-16. PubMed ID: 15120769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opioids in non-cancer pain: a life-time sentence?
    Dellemijn PL
    Eur J Pain; 2001; 5(3):333-9. PubMed ID: 11558990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
    Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
    Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
    Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
    Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Application of a seven-day buprenorphine transdermal patch in multimorbid patients on long-term ibuprofen or diclofenac].
    Böhme K; Heckes B; Thomitzek K
    MMW Fortschr Med; 2011 Jan; 152 Suppl 4():125-32. PubMed ID: 21598463
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of transdermal fentanyl on quality of life in rheumatoid arthritis.
    Berliner MN; Giesecke T; Bornhövd KD
    Clin J Pain; 2007; 23(6):530-4. PubMed ID: 17575494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
    O'Connor AB; Zwemer FL; Hays DP; Feng C
    Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems--a delphi study.
    Jacobsen R; Møldrup C; Christrup L
    Pain Med; 2009 Nov; 10(8):1442-51. PubMed ID: 19793344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine.
    Koltzenburg M; Pokorny R; Gasser UE; Richarz U
    Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transdermal opioids for cancer pain.
    Cachia E; Ahmedzai SH
    Curr Opin Support Palliat Care; 2011 Mar; 5(1):15-9. PubMed ID: 21325999
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Introduction of low dose transdermal buprenorphine -- did it influence use of potentially addictive drugs in chronic non-malignant pain patients?
    Skurtveit S; Furu K; Kaasa S; Borchgrevink PC
    Eur J Pain; 2009 Oct; 13(9):949-53. PubMed ID: 19095476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.